{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T09:46:07Z","timestamp":1747302367514},"reference-count":49,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1016\/j.bcp.2012.05.019","type":"journal-article","created":{"date-parts":[[2012,6,9]],"date-time":"2012-06-09T04:55:45Z","timestamp":1339217745000},"page":"451-458","source":"Crossref","is-referenced-by-count":6,"title":["The therapeutic effects of rGel\/BLyS fusion toxin in in vitro and in vivo models of mantle cell lymphoma"],"prefix":"10.1016","volume":"84","author":[{"given":"Mi-Ae","family":"Lyu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lan V.","family":"Pham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bokyung","family":"Sung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Archito T.","family":"Tamayo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kwang Seok","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walter N.","family":"Hittelman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence H.","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John W.","family":"Marks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min-Jeong","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard J.","family":"Ford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bharat B.","family":"Aggarwal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael G.","family":"Rosenblum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2012.05.019_bib0005","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/315340a0","article-title":"Clustering of breakpoints on chromosome 11 in human B-cell neoplasms with the t(11;14) chromosome translocation","volume":"315","author":"Tsujimoto","year":"1985","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2012.05.019_bib0010","first-page":"733","article-title":"Cloning of the t(11;14)(q13;q32) translocation breakpoints from two human leukemia cell lines","volume":"5","author":"Meeker","year":"1991","journal-title":"Leukemia"},{"key":"10.1016\/j.bcp.2012.05.019_bib0015","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/(SICI)1097-0142(19980201)82:3<567::AID-CNCR20>3.0.CO;2-Z","article-title":"Mantle cell lymphoma presenting features, response to therapy, and diagnostic factors","volume":"82","author":"Bosch","year":"1997","journal-title":"Cancer"},{"key":"10.1016\/j.bcp.2012.05.019_bib0020","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1182\/blood.V89.6.2067","article-title":"Mantle cell lymphoma: a clinicopathologic study of 80 cases","volume":"89","author":"Argatoff","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2012.05.019_bib0025","doi-asserted-by":"crossref","first-page":"7013","DOI":"10.1200\/JCO.2005.01.1825","article-title":"High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine","volume":"23","author":"Romaguera","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bcp.2012.05.019_bib0030","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/nrc2230","article-title":"Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics","volume":"7","author":"Jares","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.bcp.2012.05.019_bib0035","doi-asserted-by":"crossref","first-page":"88","DOI":"10.4049\/jimmunol.171.1.88","article-title":"Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis","volume":"171","author":"Pham","year":"2003","journal-title":"J Immunol"},{"key":"10.1016\/j.bcp.2012.05.019_bib0040","doi-asserted-by":"crossref","first-page":"4540","DOI":"10.1182\/blood-2005-10-4042","article-title":"Constitutive NF-kappaB and NFAT activation leads to stimulation of the BLyS survival pathway in aggressive B-cell lymphomas","volume":"107","author":"Fu","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2012.05.019_bib0045","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/ni0302-221","article-title":"NF-kappaB at the crossroads of life and death","volume":"3","author":"Karin","year":"2002","journal-title":"Nat Immunol"},{"key":"10.1016\/j.bcp.2012.05.019_bib0050","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1126\/science.1061965","article-title":"BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF","volume":"293","author":"Thompson","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.bcp.2012.05.019_bib0055","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1126\/science.278.5335.138","article-title":"NFAT activation induced by a CAML-interacting member of the tumor necrosis factor receptor superfamily","volume":"278","author":"von Bulow","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.bcp.2012.05.019_bib0060","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.1002\/j.1460-2075.1992.tb05482.x","article-title":"A new gene, BCM, on chromosome 16 is fused to the interleukin 2 gene by a t(4;16)(q26;p13) translocation in a malignant T cell lymphoma","volume":"11","author":"La\u00e2bi","year":"1992","journal-title":"EMBO J"},{"key":"10.1016\/j.bcp.2012.05.019_bib0065","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s00428-005-1275-6","article-title":"Expression of BAFF-R (BR3) in normal and neoplastic lymphoid tissues characterized with a newly developed monoclonal antibody","volume":"447","author":"Nakamura","year":"2005","journal-title":"Virchows Arch"},{"key":"10.1016\/j.bcp.2012.05.019_bib0070","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0360-3016(01)01446-8","article-title":"Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB","volume":"50","author":"Russo","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.bcp.2012.05.019_bib0075","first-page":"1419","article-title":"Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma","volume":"7","author":"Sunwoo","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bcp.2012.05.019_bib0080","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.bcp.2005.04.043","article-title":"Curcumin (diferuloylmethane) inhibits constitutive NF-kappaB activation, induces G1\/S arrest, suppresses proliferation, and induces apoptosis in mantle cell lymphoma","volume":"70","author":"Shishodia","year":"2005","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.bcp.2012.05.019_bib0085","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.4049\/jimmunol.178.3.1923","article-title":"Selective inhibition of IkappaB kinase sensitizes mantle cell lymphoma B cells to TRAIL by decreasing cellular FLIP level","volume":"178","author":"Rou\u00e9","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.bcp.2012.05.019_bib0090","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1081\/CNV-120030218","article-title":"Development of the proteasome inhibitor Velcade (bortezomib)","volume":"22","author":"Adams","year":"2004","journal-title":"Cancer Invest"},{"key":"10.1016\/j.bcp.2012.05.019_bib0095","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1200\/JCO.2005.11.030","article-title":"Proteasome inhibition as a novel therapeutic target in human cancer","volume":"23","author":"Rajkumar","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bcp.2012.05.019_bib0100","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1586\/14737140.6.7.983","article-title":"Use of bortezomib in B-cell non-Hodgkin's lymphoma","volume":"6","author":"Wang","year":"2006","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.bcp.2012.05.019_bib0105","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1002\/ijc.21805","article-title":"Proteasome inhibition with bortezomib: a new therapeutic strategy for non-Hodgkin's lymphoma","volume":"119","author":"Leonard","year":"2006","journal-title":"Int J Cancer"},{"key":"10.1016\/j.bcp.2012.05.019_bib0110","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1200\/JCO.2005.02.050","article-title":"Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma","volume":"23","author":"O\u2019Connor","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bcp.2012.05.019_bib0115","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1200\/JCO.2005.03.108","article-title":"Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma","volume":"23","author":"Goy","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bcp.2012.05.019_bib0120","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1200\/JCO.2006.07.9665","article-title":"Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma","volume":"24","author":"Fisher","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bcp.2012.05.019_bib0125","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/annonc\/mdn656","article-title":"Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study","volume":"20","author":"Goy","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bcp.2012.05.019_bib0130","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1158\/1535-7163.MCT-06-0254","article-title":"The rGel\/BLyS fusion toxin specifically targets malignant B cells expressing the BLyS receptors BAFF-R, TACI, and BCMA","volume":"6","author":"Lyu","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.bcp.2012.05.019_bib0135","doi-asserted-by":"crossref","first-page":"424","DOI":"10.5858\/2003-127-0424-COMCLC","article-title":"Characterization of 4 mantle cell lymphoma cell lines","volume":"127","author":"Amin","year":"2003","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.bcp.2012.05.019_bib0140","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","article-title":"Quantitative analysis of dose\u2013effect relationships: the combined effects of multiple drugs or enzyme inhibitors","volume":"22","author":"Chou","year":"1984","journal-title":"Adv Enzyme Regul"},{"key":"10.1016\/j.bcp.2012.05.019_bib0145","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/S0076-6879(00)19055-X","article-title":"Assay for redox-sensitive factor","volume":"319","author":"Chaturvedi","year":"2000","journal-title":"Methods Enzymol"},{"key":"10.1016\/j.bcp.2012.05.019_bib0150","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1084\/jem.193.4.417","article-title":"IkappaB kinase alpha is essential for mature B cell development and function","volume":"193","author":"Kaisho","year":"2001","journal-title":"J Exp Med"},{"key":"10.1016\/j.bcp.2012.05.019_bib0155","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1101\/gad.13.4.400","article-title":"Rel-dependent induction of A1 transcription is required to protect B cells from antigen receptor ligation-induced apoptosis","volume":"13","author":"Grumont","year":"1999","journal-title":"Genes Dev"},{"key":"10.1016\/j.bcp.2012.05.019_bib0160","doi-asserted-by":"crossref","first-page":"4519","DOI":"10.1038\/sj.onc.1204623","article-title":"The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications","volume":"20","author":"Hideshima","year":"2001","journal-title":"Oncogene"},{"key":"10.1016\/j.bcp.2012.05.019_bib0165","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1182\/blood.V97.9.2798","article-title":"Constitutive NF-kappaB maintains high expression of a characteristic gene network, including CD40, CD86, and a set of antiapoptotic genes in Hodgkin\/Reed-Sternberg cells","volume":"97","author":"Hinz","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2012.05.019_bib0170","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/0-387-24361-5_5","article-title":"Pro-apoptotic and anti-apoptotic effects of tumor necrosis factor in tumor cells. Role of nuclear transcription factor NF-kappaB","volume":"126","author":"Aggarwal","year":"2005","journal-title":"Cancer Treat Res"},{"key":"10.1016\/j.bcp.2012.05.019_bib0175","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1084\/jem.191.10.1721","article-title":"Protein kinase B regulates T lymphocyte survival, nuclear factor kappaB activation, and Bcl-x(L) levels in vivo","volume":"191","author":"Jones","year":"2000","journal-title":"J Exp Med"},{"key":"10.1016\/j.bcp.2012.05.019_bib0180","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1128\/MCB.20.5.1626-1638.2000","article-title":"Akt suppresses apoptosis by stimulating the transactivation potential of the RelA\/p65 subunit of NF-\u03baB","volume":"20","author":"Madrid","year":"2000","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.bcp.2012.05.019_bib0185","first-page":"3504","article-title":"A direct linkage between the phosphoinositide3-kinase-Akt signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells","volume":"60","author":"Sekulic","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.bcp.2012.05.019_bib0190","doi-asserted-by":"crossref","first-page":"5347","DOI":"10.1200\/JCO.2005.13.466","article-title":"Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma","volume":"23","author":"Witzig","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bcp.2012.05.019_bib0195","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0092-8674(00)80405-5","article-title":"Akt phosphorylation of Bad couples survival signals to the cell-intrinsic death machinery","volume":"91","author":"Datta","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2012.05.019_bib0200","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1517\/14728222.11.7.929","article-title":"Novel therapeutic targets in mantle cell lymphoma","volume":"11","author":"Martin","year":"2007","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.bcp.2012.05.019_bib0205","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/j.1365-2141.2007.06908.x","article-title":"A phase II clinical trial of intensive chemotherapy followed by consolidative stem cell transplant: long-term follow-up in newly diagnosed mantle cell lymphoma","volume":"140","author":"Evens","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bcp.2012.05.019_bib0210","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1200\/jco.2003.09.057","article-title":"Flavopiridol in untreated or relapsed mantle-cell lymphoma: results of a phase II study of the National Cancer Institute of Canada Clinical Trials Group","volume":"21","author":"Kouroukis","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bcp.2012.05.019_bib0215","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1182\/blood-2004-03-1091","article-title":"Anti-tumor activity of rituximab plus thalidomide in patients with relapsed\/refractory mantle cell lymphoma","volume":"104","author":"Kaufmann","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2012.05.019_bib0220","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ccr.2004.09.003","article-title":"Nuclear factor-\u03baB: the enemy within","volume":"6","author":"Aggarwal","year":"2004","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bcp.2012.05.019_bib0225","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/ncponc0555","article-title":"Bortezomib efficacy comparison in solid tumors and hematologic malignancies","volume":"3","author":"Caravita","year":"2006","journal-title":"Nat Clin Pract Oncol"},{"key":"10.1016\/j.bcp.2012.05.019_bib0230","first-page":"8226","article-title":"The molecular signature of mantle cell lymphoma reveals multiple signals favoring cell survival","volume":"63","author":"Mart\u00ednez","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.bcp.2012.05.019_bib0235","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/0167-5699(94)90276-3","article-title":"CD20: a regulator of cell-cycle progression of B lymphocytes","volume":"15","author":"Tedder","year":"1994","journal-title":"Immunol Today"},{"key":"10.1016\/j.bcp.2012.05.019_bib0240","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1159\/000082102","article-title":"The biology of CD20 and its potential as a target for mAb therapy","volume":"8","author":"Cragg","year":"2005","journal-title":"Curr Dir Autoimmun"},{"key":"10.1016\/j.bcp.2012.05.019_bib0245","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients responsed to a four-dose treatment program","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J Clin Oncol"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295212003942?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295212003942?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,1,17]],"date-time":"2022-01-17T04:05:22Z","timestamp":1642392322000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295212003942"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8]]},"references-count":49,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["S0006295212003942"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2012.05.019","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2012,8]]}}}